Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $136,826.00 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ra Capital Management, L.P. sold 369,800 shares of the company’s stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $0.37, for a total value of $136,826.00. Following the completion of the sale, the insider directly owned 381,717 shares in the company, valued at approximately $141,235.29. The trade was a 49.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Thursday, June 11th, Ra Capital Management, L.P. sold 262,503 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.38, for a total value of $99,751.14.
• On Wednesday, June 10th, Ra Capital Management, L.P. sold 45,923 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total value of $16,991.51.
• On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total value of $64,736.64.
• On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.67, for a total value of $58,618.30.
• On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.71, for a total value of $267,333.46.

Werewolf Therapeutics Stock Down 3.3%

Shares of HOWL stock opened at $0.38 on Friday. The stock has a market cap of $18.52 million, a price-to-earnings ratio of -0.31 and a beta of 0.29. The business’s fifty day moving average is $0.66 and its 200 day moving average is $0.71. Werewolf Therapeutics, Inc. has a twelve month low of $0.36 and a twelve month high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.04. Equities research analysts expect that Werewolf Therapeutics, Inc. will post -1.08 earnings per share for the current fiscal year.

Institutional Trading of Werewolf Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC increased its position in Werewolf Therapeutics by 48.6% in the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after buying an additional 221,766 shares in the last quarter. Susquehanna International Group LLP grew its position in shares of Werewolf Therapeutics by 16.9% during the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after purchasing an additional 13,439 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Werewolf Therapeutics during the third quarter worth about $304,000. Vanguard Group Inc. grew its position in shares of Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after purchasing an additional 109,796 shares in the last quarter. Finally, Bank of America Corp DE grew its position in shares of Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after purchasing an additional 25,882 shares in the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Wall Street Zen downgraded Werewolf Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $3.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.